Demographic features, malignancy history, rheumatological, clinical and ultrasonographic manifestations, time to onset, autoantibody profile and treatment of the seven patients developing synovitis. Active synovitis was defined by the presence of power Doppler signal.
| Pt | Sex | Age (years) | Malignancy (treatment) | Clinical manifestations | Interval (weeks) | Autoantibody assessment | US | Diagnosis | Treatment |
| 1 | F | 55 | RCC (nivolumab) | Simmetric polyarthritis | 3 | RF, ACPA, ANA neg | Active synovitis | RA | PDN 12.5 mg/daily |
| 2 | F | 61 | Melanoma (nivolumab) | Simmetric polyarthritis | 3 | RF 22 UI/mL, ACPA >300 UI/mL, ANA+ (sp), a-SSA+ | Active synovitis | RA | PDN 10 mg/daily MTX 10 mg/weekly |
| 3 | M | 68 | NSCLC (nivolumab) | Monoartrhritis | 8 | RF, ACPA, ANA neg | Synovitis | UA | NSAIDs |
| 4 | F | 72 | NSCLC (nivolumab) | Polyarthritis | 18 | RF, ACPA, ANA neg | Synovitis | UA | PDN 12.5 mg/daily |
| 5 | M | 77 | NSCLC (nivolumab) | Oligoarthritis | 4 | RF, ACPA, ANA neg | Synovitis | UA | NSAIDs |
| 6 | M | 70 | NSCLC (nivolumab) | Simmetric polyarthritis | 2 | RF, ACPA, ANA neg | Active synovitis | UA | PDN 10 mg/daily |
| 7 | M | 61 | NSCLC (nivolumab) | Simmetric polyarthritis | 36 | RF, ACPA, ANA neg | Synovitis | UA | PDN 10 mg/daily |
ACPA, anti-citrullinated protein antibodies; ANA, anti-nuclear antibodies; a-SSA, anti-SSA; MTX, Methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; PDN, prednisone; RA, rheumatoid arthritis; RCC, renal cell carcinoma; RF, rheumatoid factor; sp, Speckled; UA, undifferentiated arthritis; US, ultrasonographic.